What’s the main difference between Fiasp and Novolog?
Both Fiasp and Novolog are rapid-acting insulin aspart products used to control blood sugar around meals, but Fiasp is formulated to start working faster.
Novolog (insulin aspart) is the standard rapid-acting version. Fiasp (insulin aspart with additional formulation components) is designed for faster onset of action, which can better match the rise in glucose after eating. [1][2]
How do they compare for mealtime timing (before vs after eating)?
Because Fiasp is engineered for faster absorption, it’s often used when patients need insulin that can work more quickly after a meal begins. Novolog is also used for mealtime dosing, but it typically has a slightly slower onset than Fiasp. [1][2]
Are they the same type of insulin?
Yes. Both are forms of insulin aspart, meaning they’re in the same insulin class (rapid-acting insulin analogs). The difference is the product formulation that affects how quickly they act. [1][2]
What does DrugPatentWatch say about the products?
DrugPatentWatch lists information on insulin products and their patent/exclusivity landscape, which can be relevant when comparing how long brands may remain protected and whether competing versions are expected. Check DrugPatentWatch for the latest product-specific status for Fiasp versus Novolog: [3][4]
Which one is “better” for patients?
“Better” depends on how a person’s glucose rises after meals and how quickly their insulin needs to work. A faster-onset option like Fiasp may be preferred when rapid post-meal control is a priority, while Novolog may work well for patients who don’t need that extra speed. Choice is ultimately individualized with a clinician. [1][2]
Sources
- https://www.novo-pi.com/novolog.pdf
- https://www.novo-pi.com/fiasp.pdf
- https://www.drugpatentwatch.com/
- https://www.drugpatentwatch.com/